Cemdisiran Quarterly siRNA Shows Phase 3 MG-ADL Win But No Mechanistic Precedent

Regeneron Reports Strong Q3 Earnings and Key Pipeline Progress

Regeneron reported a strong third quarter in 2026, exceeding consensus with $5.1 billion in earnings, a 36% increase over Q3 2025. This performance was driven by record sales of key products including Dupixent ($6.5 billion global sales), Eylea HD ($699 million U.S. sales), and Libtayo ($550 million). The company also highlighted several upcoming pipeline catalysts, such as an anticipated FDA decision in November for cemdisiran, a subcutaneous siRNA therapy for myasthenia gravis. Further advancements include four-year follow-up data for Libtayo in cutaneous squamous cell carcinoma, showing a 37% reduction in death risk, and Phase 3 data for olatorepatide, a dual GLP-1/GIP receptor agonist, demonstrating up to a 19% weight reduction. Regeneron also renewed its partnership with Sanofi, securing $1 billion upfront for next-generation inflammation medicines.

• Regeneron achieved a "clean sweep" in Q3 2026, reporting $5.1 billion in revenue, significantly surpassing analyst expectations and marking a 36% increase from the previous year. This robust financial growth was fueled by record net sales from its blockbuster products: Dupixent, which cleared $6.5 billion in global sales; Eylea HD, with U.S. sales leaping 62% to $699 million; and the cancer immunotherapy Libtayo, which more than doubled its year-over-year sales to $550 million.
• The company anticipates critical regulatory and clinical milestones. An FDA decision is expected in November for cemdisiran, a subcutaneous siRNA therapy targeting C5 for myasthenia gravis, potentially offering the first quarterly subcutaneous dosing. Additionally, updated four-year follow-up data from the Phase 3 C-POST trial for Libtayo in high-risk cutaneous squamous cell carcinoma demonstrated a sustained 37% reduction in the risk of death, reinforcing its efficacy.
• Regeneron is progressing its obesity program with olatorepatide, a dual GLP-1/GIP receptor agonist, which showed up to a 19% reduction in body weight in a China-based Phase 3 trial, with global trials planned. Furthermore, the company strengthened its long-standing partnership with Sanofi, securing a $1 billion upfront payment and up to $7 billion in potential milestones to jointly develop four next-generation antibodies for immune-mediated conditions, signaling a renewed collaborative focus.

Cemdisiran's Competitive Edge in Myasthenia Gravis

Cemdisiran is an siRNA targeting complement component 5 (C5) evaluated as monotherapy and in combination with pozelimab in generalised myasthenia gravis. Other complement C5 inhibitors trialled in acetylcholine receptor antibody-positive generalised myasthenia gravis include peptide and monoclonal antibody inhibitors studied in randomized, double-blind and open-label designs.

Addressing Unmet Needs in Myasthenia Gravis Treatment

Current treatment of myasthenia gravis achieves remission or minimal manifestations in many patients, but control often requires prolonged immunosuppression with significant toxicity. Disease heterogeneity in clinical presentation, immunopathogenesis and drug response complicates treatment strategy, and a small subset develops treatment-refractory disease.

• Corticosteroid burden and limited steroid-sparing success: Long-term systemic steroid administration carry considerable risks and adverse events. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients in a juvenile cohort, while non-achievers of the ≤5 mg/day oral corticosteroid dose target had less frequent incident confirmed diabetes in the JMDC population and new osteoporotic fractures in the LSEHS population were less frequent in target achievers than in non-achievers, with higher total and MG-related costs in non-achievers.

• Incomplete responses, relapses and refractoriness: Approximately 10-15% of patients with generalized AChR antibody-positive MG develop refractoriness to standard immunosuppressive therapies. Thymectomy reduced mean QMG scores from 7.7 to 2.4 in seven juvenile patients, though residual relapses were observed, and of 92 patients undergoing mycophenolate mofetil taper after achieving either pharmacologic remission or minimal manifestations status, 30 relapsed with a mean dose at time of relapse of 888 mg/day.

• Variable effectiveness of immunosuppressants and IVIG: Chronic intravenous immunoglobulin therapy, administered to 70% of juvenile patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year. Timing of azathioprine initiation showed no significant correlation with relapse frequency, and only duration of disease of >10 years (odds ratio 9.5, 95% confidence interval 2.4-36.9, P = 0.001) was significantly associated with remission on azathioprine.

• Comorbidity, age-related vulnerability and external triggers: Despite late-onset MG having more comorbidities that might interfere with treatment and outcome, therapeutic management does not seem to differ between early-onset and late-onset groups, with diabetes more frequent in LOMG vs EOMG (2,2% vs 5%, p = 0.017) and the highest rate of serious side effects (20%) in late-onset MG and the lowest (4%) in early-onset disease. Mortality was higher and disease was more severe in late-onset (>50 years) patients, with four patients dying due to COVID-19 infection, and exacerbation including myasthenic crisis was reported after pembrolizumab treatment in a 75-year-old man with stable MG.

The Evolving Myasthenia Gravis Treatment Landscape

Myasthenia gravis (MG) treatment has shifted from broad immunosuppression with corticosteroids, azathioprine, cyclosporine, and mycophenolate mofetil, plasma exchange and intravenous immunoglobulin toward target-specific immunotherapies. FDA-approved neonatal Fc receptor (FcRn) inhibitors (efgartigimod, rozanolixizumab, nipocalimab) and complement inhibitors (eculizumab, ravulizumab, zilucoplan) have transformed the treatment paradigm for generalized MG. FcRn inhibitors significantly improve Myasthenia Gravis Activities of Daily Living (MG-ADL) scores in acetylcholine receptor (AChR) and muscle-specific tyrosine kinase (MuSK) antibody-positive patients, with rozanolixizumab and nipocalimab uniquely approved for MuSK-MG, while complement inhibitors show rapid efficacy in refractory anti-AChR MG, with zilucoplan enabling self-administration by daily subcutaneous injections.

Pivotal trial data demonstrate consistent, clinically meaningful benefit across MG-specific outcomes. In a meta-analysis of six randomized controlled trials (n = 739) and four open-label extensions (n = 588) evaluating eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, and batoclimab, both drug classes significantly improved mean changes from baseline versus placebo in Myasthenia Gravis Activities of Daily Living [MD 1.7, 95% confidence interval (CI) 1.1-2.3], Quantitative Myasthenia Gravis [MD 2.7, 95%(CI)1.8-3.5], Myasthenia Gravis Composite [MD 6.3, 95%(CI) 5-7.6], MGQoL15r [MD 3.4, 95%(CI)1.2-5.6], and Neuro-QoL [MD 4.5, 95%(CI)1.2-7.7]. Odds of achieving clinically meaningful MG-ADL and QMG improvements were more than doubled (ORs 2.7 and 3.5), and risks of clinical worsening and rescue therapy use were reduced by 72% and 48%, respectively. A network meta-analysis of Phase III placebo-controlled trials of efgartigimod IV, inebilizumab, nipocalimab, ravulizumab, rozanolixizumab, and zilucoplan found efgartigimod IV ranked highest across nearly all endpoints considering the probability of being the most effective and SUCRA values, with the lowest NNTs for QMG improvement (2.18 [≥3-point]; 1.88 [≥5-point]) and MG-ADL NNTs of 2.77 (at least 3-point) and 1.94 (at least 5-point). Repeated cycles of rozanolixizumab resulted in consistent improvements across cycles, with 188/196 (95.9%) patients receiving ≥1 treatment cycle and 127 (64.8%) receiving ≥2 symptom-driven cycles, and complement inhibitor open-label extensions showed durable benefit up to 156 weeks with 30% of patients reducing corticosteroid doses.

Real-world and special-population studies have extended these findings beyond pivotal populations, including very-late-onset MG, extreme elderly, seronegative and refractory disease, and impending myasthenic crisis. In twelve patients with mean age of 82.9 ± 2.5 years treated with efgartigimod, MG-ADL scores decreased by 52.2% ± 30.8% (from 10.9 ± 2.7 to 3.6 ± 2.1), QMG scores by 36.6% ± 28.4% (from 18.2 ± 7.0 to 11.7 ± 8.3), and MGC scores by 48.2% ± 33.4% (from 17.8 ± 7.5 to 9.0 ± 8.6), with clinically meaningful improvement achieved by 91.7% (11/12) at 1.3 ± 0.5 weeks. In 62 patients with very late-onset MG (onset ≥ 65 years), the cumulative minimal symptom expression achievement rate was 41.9% (26/62) with significant glucocorticoid dosage reduction. In 30 patients with double-seronegative generalized MG, MGII decreased by 11.92 points (p < 0.01) with 72% responders, and in 51 AChR antibody-positive impending myasthenic crisis patients receiving efgartigimod (n = 30) or IVIg (n = 21), MG-ADL improvement ≥7 points was 90.0% vs. 57.1% and minimal symptom expression was 80.0% vs. 14.3%, with mean improvement rates of 91.5% vs. 60.7%. Adverse events include infections and hypersensitivity reactions requiring vaccination and close monitoring, with rozanolixizumab treatment-emergent adverse events in 169/188 (89.9%) mostly mild to moderate, and pharmacovigilance signal detection identifying previously unlabeled signals for eculizumab, ravulizumab, zilucoplan, efgartigimod and rozanolixizumab.

Beyond Myasthenia Gravis: Cemdisiran's Broader Potential

Cemdisiran, an N-acetylgalactosamine-conjugated RNA interference therapeutic that suppresses liver production of complement component 5 (C5), is being trialled in paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy. In PNH it has been evaluated as monotherapy and in combination with C5 antibody inhibitors, while in IgA nephropathy it has been evaluated in combination with the standard of care.

Regeneron's Pipeline Catalysts Signal Broad Market Expansion

Regeneron's recent financial results paint a picture of a company firing on all cylinders, with record sales from its flagship products providing a robust foundation for future growth. This strong commercial performance is strategically complemented by a pipeline poised to deliver significant catalysts, signaling an aggressive push into high-value therapeutic areas.

The upcoming FDA decision for cemdisiran in myasthenia gravis represents a pivotal moment. The literature highlights the profound impact of complement C5 inhibition in generalized myasthenia gravis, with agents like zilucoplan and eculizumab demonstrating rapid and clinically meaningful improvements. Cemdisiran, as a subcutaneous siRNA, could offer a significant advantage in patient convenience, potentially improving adherence and quality of life, though post-approval monitoring for adverse events, such as injection-site reactions or infection risk, will be crucial.

Another major pipeline highlight is olatorepatide, a dual GLP-1/GIP receptor agonist. The cardiometabolic market, particularly for obesity and type 2 diabetes, is experiencing explosive growth. Dual agonists like tirzepatide have shown superior weight loss and glycemic control compared to GLP-1 mono-agonists. Olatorepatide's Phase 3 data, indicating up to a 19% weight reduction, positions Regeneron to enter this lucrative space. However, the competitive landscape is fierce, with established therapies boasting extensive clinical data, including cardiovascular outcomes. Olatorepatide will need to clearly differentiate itself to carve out a substantial market share.

Meanwhile, the four-year follow-up data for Libtayo in cutaneous squamous cell carcinoma reinforces its long-term value, showing a 37% reduction in death risk. This strengthens its position in advanced cSCC, a disease where PD-1 inhibitors have revolutionized treatment. However, it's important to note that studies suggest cemiplimab's efficacy may be less pronounced in specific cSCC subtypes, such as Marjolin ulcer, necessitating careful patient selection. The continued strong performance of Dupixent across multiple T2 inflammatory diseases and Eylea HD in retinal conditions further solidifies Regeneron's market presence. The company's renewed partnership with Sanofi for next-generation inflammation medicines underscores a strategic commitment to innovation and pipeline diversification, balancing established successes with calculated risks in emerging therapeutic frontiers.